Q2 FY2026 EarningsQ2 FY2026 results delivered a top-line beat with revenue of $4.14B vs. $4.03B consensus, driven by a 43% YoY LC surge in innovative brands (AUSTEDO, AJOVY, UZEDY). Despite the revenue beat, Normalized EPS of $0.02 significantly missed the $0.11 consensus due to a $726M acquisition charge for Emalex recorded in Q2. Management raised full-year FY26 revenue guidance for all three innovative brands while maintaining consolidated EPS and FCF outlooks, absorbing the Emalex impact.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Teva Pharmaceutical Industries(TEVA) the Revenue is 4.142 B (-0.81%), Beat estimate;the EBIT is 375 M (-66.9%), Beat estimate;the EPS is -0.49 (-296%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
4.14B0.81%
4.03B3.51%
+0.11B2.70%
EBITExceed expectations
0.38B66.90%
0.32B71.34%
+0.05B4.44%
EPSMiss expectations
-0.49296.00%
-0.1458158.31%
-0.3442137.69%
Upcoming earnings report - Q3 FY2026
Available dateNov 3, 2026
Estimate Revenue$4.242 B
Estimate EBIT$1.21 B
Estimate EPS$0.4785
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf